A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Sep 2018.